NDAORALTABLET
Approved
Nov 2023
Lifecycle
Growth
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA (vonoprazan fumarate) is an oral potassium-competitive acid blocker (KCAB) approved in November 2023 for acid-related gastrointestinal conditions. It represents a new mechanistic class for gastric acid suppression, offering an alternative to proton pump inhibitors (PPIs) with potentially faster onset and sustained efficacy.
$0.046BPart D
GrowthGrowing
4.3 years to LOEEarly-stage product in rapid growth phase with expanding market penetration; commercial teams are scaling field infrastructure and MSL networks to capture PPI-switching opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.
Started Oct 2023
30 enrolled
Gastric Ulcer
Why This Matters for Your Career
Worked on VOQUEZNA at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.